vs
Liberty Energy Inc.（LBRT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Liberty Energy Inc.的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs 2.2%，领先10.5%），Revvity同比增速更快（5.9% vs 4.5%），过去两年Revvity的营收复合增速更高（9.0% vs -6.2%）
Liberty Energy Inc.是北美领先的能源服务供应商，专注为油气运营企业提供水力压裂及完井解决方案，服务覆盖美国主要页岩产区，供应低排放作业设备及定制化支持，帮助提升油气井生产效率。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LBRT vs RVTY — 直观对比
营收规模更大
LBRT
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出1.4%
4.5%
净利率更高
RVTY
高出10.5%
2.2%
两年增速更快
RVTY
近两年复合增速
-6.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $22.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 2.2% | 14.5% |
| 净利率 | 2.2% | 12.7% |
| 营收同比 | 4.5% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.14 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LBRTRVTY
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $947.4M | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $977.5M | $664.8M | ||
| Q4 24 | $943.6M | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M |
净利润LBRTRVTY
| Q1 26 | $22.6M | — | ||
| Q4 25 | $13.7M | $98.4M | ||
| Q3 25 | $43.1M | $46.7M | ||
| Q2 25 | $71.0M | $53.9M | ||
| Q1 25 | $20.1M | $42.2M | ||
| Q4 24 | $51.9M | $94.6M | ||
| Q3 24 | $73.8M | $94.4M | ||
| Q2 24 | $108.4M | $55.4M |
毛利率LBRTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 20.6% | — | ||
| Q3 25 | 18.7% | 53.6% | ||
| Q2 25 | 22.1% | 54.5% | ||
| Q1 25 | 22.1% | 56.5% | ||
| Q4 24 | 21.4% | — | ||
| Q3 24 | 26.2% | 56.3% | ||
| Q2 24 | 27.9% | 55.7% |
营业利润率LBRTRVTY
| Q1 26 | 2.2% | — | ||
| Q4 25 | 1.9% | 14.5% | ||
| Q3 25 | -0.3% | 11.7% | ||
| Q2 25 | 3.6% | 12.6% | ||
| Q1 25 | 1.9% | 10.9% | ||
| Q4 24 | 2.6% | 16.3% | ||
| Q3 24 | 9.4% | 14.3% | ||
| Q2 24 | 12.2% | 12.4% |
净利率LBRTRVTY
| Q1 26 | 2.2% | — | ||
| Q4 25 | 1.3% | 12.7% | ||
| Q3 25 | 4.5% | 6.7% | ||
| Q2 25 | 6.8% | 7.5% | ||
| Q1 25 | 2.1% | 6.4% | ||
| Q4 24 | 5.5% | 13.0% | ||
| Q3 24 | 6.5% | 13.8% | ||
| Q2 24 | 9.3% | 8.0% |
每股收益（稀释后）LBRTRVTY
| Q1 26 | $0.14 | — | ||
| Q4 25 | $0.08 | $0.86 | ||
| Q3 25 | $0.26 | $0.40 | ||
| Q2 25 | $0.43 | $0.46 | ||
| Q1 25 | $0.12 | $0.35 | ||
| Q4 24 | $0.31 | $0.77 | ||
| Q3 24 | $0.44 | $0.77 | ||
| Q2 24 | $0.64 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $699.1M | $919.9M |
| 总债务越低越好 | $7.1M | — |
| 股东权益账面价值 | $1.9B | $7.3B |
| 总资产 | $4.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资LBRTRVTY
| Q1 26 | $699.1M | — | ||
| Q4 25 | $27.6M | $919.9M | ||
| Q3 25 | $13.5M | $931.4M | ||
| Q2 25 | $19.6M | $991.8M | ||
| Q1 25 | $24.1M | $1.1B | ||
| Q4 24 | $20.0M | $1.2B | ||
| Q3 24 | $23.0M | $1.2B | ||
| Q2 24 | $30.0M | $2.0B |
总债务LBRTRVTY
| Q1 26 | $7.1M | — | ||
| Q4 25 | $246.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $190.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益LBRTRVTY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $2.1B | $7.3B | ||
| Q3 25 | $2.1B | $7.4B | ||
| Q2 25 | $2.0B | $7.6B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.7B | ||
| Q3 24 | $2.0B | $7.9B | ||
| Q2 24 | $1.9B | $7.9B |
总资产LBRTRVTY
| Q1 26 | $4.4B | — | ||
| Q4 25 | $3.6B | $12.2B | ||
| Q3 25 | $3.5B | $12.1B | ||
| Q2 25 | $3.4B | $12.4B | ||
| Q1 25 | $3.4B | $12.4B | ||
| Q4 24 | $3.3B | $12.4B | ||
| Q3 24 | $3.3B | $12.8B | ||
| Q2 24 | $3.2B | $13.4B |
负债/权益比LBRTRVTY
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 13.1% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流LBRTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $195.4M | $182.0M | ||
| Q3 25 | $51.5M | $138.5M | ||
| Q2 25 | $170.6M | $134.3M | ||
| Q1 25 | $192.1M | $128.2M | ||
| Q4 24 | $177.3M | $174.2M | ||
| Q3 24 | $244.5M | $147.9M | ||
| Q2 24 | $248.2M | $158.6M |
自由现金流LBRTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-10.0M | $161.8M | ||
| Q3 25 | $-67.2M | $120.0M | ||
| Q2 25 | $33.1M | $115.5M | ||
| Q1 25 | $58.2M | $112.2M | ||
| Q4 24 | $-26.2M | $149.8M | ||
| Q3 24 | $77.9M | $125.6M | ||
| Q2 24 | $112.2M | $136.6M |
自由现金流率LBRTRVTY
| Q1 26 | — | — | ||
| Q4 25 | -1.0% | 21.0% | ||
| Q3 25 | -7.1% | 17.2% | ||
| Q2 25 | 3.2% | 16.0% | ||
| Q1 25 | 6.0% | 16.9% | ||
| Q4 24 | -2.8% | 20.5% | ||
| Q3 24 | 6.8% | 18.4% | ||
| Q2 24 | 9.7% | 19.7% |
资本支出强度LBRTRVTY
| Q1 26 | 13.1% | — | ||
| Q4 25 | 19.8% | 2.6% | ||
| Q3 25 | 12.5% | 2.6% | ||
| Q2 25 | 13.2% | 2.6% | ||
| Q1 25 | 13.7% | 2.4% | ||
| Q4 24 | 21.6% | 3.4% | ||
| Q3 24 | 14.6% | 3.3% | ||
| Q2 24 | 11.7% | 3.2% |
现金转化率LBRTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 14.28× | 1.85× | ||
| Q3 25 | 1.20× | 2.97× | ||
| Q2 25 | 2.40× | 2.49× | ||
| Q1 25 | 9.55× | 3.03× | ||
| Q4 24 | 3.42× | 1.84× | ||
| Q3 24 | 3.31× | 1.57× | ||
| Q2 24 | 2.29× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LBRT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
